A retrospective review of the effect of metformin in metastatic prostate cancer
Journal of Clinical Oncology Feb 28, 2020
Lam SY, et al. - In order to investigate the anticancer potential of metformin on metastatic prostate cancer, researchers performed this retrospective review. The patients had metastatic prostate cancer and were 281 in total, with a mean age of 70 ± 10. The significance of patients receiving metformin in addition to their current treatment was determined. Using PCWG3 and RECIST criteria, progression-free survival (PFS) was assessed. The evaluation of 6-month (6MO) PSA response and overall survival (OS) was also carried out. Lower risk of progression was observed in metformin users vs non-users in the metastatic hormone-sensitive prostate cancer group. A significantly higher risk of progression was evident among metformin users vs non-users within the metastatic castration resistant prostate cancer group. The estimated median overall survival was 81.5 months. Metformin groups showed a significant difference in survival time. Overall, findings revealed no significant differences in 6MO PSA response or PFS. In terms of OS, a significant difference was evident among patients who were included in the metformin group and those who were not.Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
55 lakhs+ doctors trust M3 globally
Unlimited access to original articles by experts
Secure: we never sell your data
Signing up takes less than 2 mins